company background image
PPCB logo

Propanc Biopharma OTCPK:PPCB Stock Report

Last Price

US$0.0028

Market Cap

US$219.9k

7D

-1.4%

1Y

-99.4%

Updated

25 Mar, 2024

Data

Company Financials

Propanc Biopharma, Inc.

OTCPK:PPCB Stock Report

Market Cap: US$219.9k

PPCB Stock Overview

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia.

PPCB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Propanc Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Propanc Biopharma
Historical stock prices
Current Share PriceUS$0.0028
52 Week HighUS$0.70
52 Week LowUS$0.0023
Beta1.66
1 Month Change-3.10%
3 Month Change-79.93%
1 Year Change-99.38%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

PPCBUS BiotechsUS Market
7D-1.4%-0.06%2.1%
1Y-99.4%9.8%30.4%

Return vs Industry: PPCB underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: PPCB underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is PPCB's price volatile compared to industry and market?
PPCB volatility
PPCB Average Weekly Movement29.4%
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: PPCB's share price has been volatile over the past 3 months.

Volatility Over Time: PPCB's weekly volatility has decreased from 53% to 29% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20072James Nathanielszhttps://www.propanc.com

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells.

Propanc Biopharma, Inc. Fundamentals Summary

How do Propanc Biopharma's earnings and revenue compare to its market cap?
PPCB fundamental statistics
Market capUS$219.91k
Earnings (TTM)-US$2.73m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PPCB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$2.73m
Earnings-US$2.73m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.038
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-27.7%

How did PPCB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.